Related references
Note: Only part of the references are listed.Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE
Steven Grunberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Moderately Emetogenic (MEC) Chemotherapy in Patients with Breast Cancer.:
T. Webb et al.
CANCER RESEARCH (2010)
Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy
Christian Hammer et al.
PHARMACOGENOMICS (2010)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
Bernardo L. Rapoport et al.
SUPPORTIVE CARE IN CANCER (2010)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer
B. Rapoport et al.
EJC SUPPLEMENTS (2009)
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
Lieven Annemans et al.
SUPPORTIVE CARE IN CANCER (2008)
Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations
Karin Jordan et al.
ONCOLOGIST (2007)
New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations
Edward B. Rubenstein et al.
CANCER JOURNAL (2006)
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Mark G. Kris et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:: effect of gender on treatment response
PJ Hesketh et al.
SUPPORTIVE CARE IN CANCER (2006)
Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials
N Neymark et al.
SUPPORTIVE CARE IN CANCER (2005)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
DG Warr et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
CC Sun et al.
SUPPORTIVE CARE IN CANCER (2005)
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
A Ihbe-Heffinger et al.
ANNALS OF ONCOLOGY (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
